Stem Cells Treatment for Bilateral Limbic Associated Keratopathy (HULPOFT)

Phase IIa Clinical Trial to Study the Feasability and Security of the Expanded Autologous Stem Cells (ASC) From Lipoaspirate in the Bilateral Limbic Associated Keratopathy Treatment

Evaluate the use of the autologous ASC for the treatment of bilateral limbic associated keratopathy

Intralesional use by inject of adipose derived stem cells

Inclusion Criteria:

1. -Signed informed consent

2. -Previously diagnosed bilateral limbic obstruction

3. -Men and women over 18 years old. Good general state of health according to the findings of the clinical history and the physical examination

4. -Suffering chronic keratopathy accomplishing the following criteria:

   • Confirmed limbic obstruction with an impression cytology
   • Repeated usual treatment failure for this pathology

Exclusion Criteria:

1. -Having suffered a neoplasia in the previous 5 years
2. -Local anesthesia allergies
3. -Patients having participate in any other study in the previous 90 days to the inclusion
4. -Patients on medication with tacrolimus or cyclosporine in the 4 previous week to the cellular therapy
5. -Any medical or psychiatric illness that, in the investigator opinion, could suppose a reason for the study exclusion
6. -Patients with any type of medical or psychiatric disease which, in the opinion of the investigator, could be grounds for exclusion from study
7. -Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema infection, whether active or latent
8. -Patients who have suffering major surgery or severe trauma in the prior 6 months
9. -Pregnant or breastfeeding women